Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
The Effects of Estrogen Withdrawal on Mood Symptoms in Women
This study is currently recruiting participants.
Verified by National Institutes of Health Clinical Center (CC), January 2008
Sponsored by: National Institute of Mental Health (NIMH)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00060736

This study evaluates the effects on mood when stopping estrogen replacement therapy.

The purpose of this study is to investigate the effects of estrogen levels on perimenopausal depression. This study will examine short-term withdrawal of estrogen in women whose mood had improved with estrogen therapy.

Perimenopause-related mood disorders cause significant distress in a large number of women. Evidence suggests that estradiol may have beneficial effects in women with perimenopausal depression. However, the effect of declining estradiol secretion during perimenopause has not been fully examined.

Peri- and post-menopausal women who experience a remission of perimenopause-related depression symptoms while on estrogen therapy and a control group of healthy volunteers on hormone replacement therapy (HRT) will be switched from their current form of HRT to estradiol for a 3-week period; volunteers will also complete symptom ratings to confirm the absence of mood symptoms. Participants will then be randomly assigned to either continue estradiol or take a placebo (an inactive pill) for an additional 3 weeks. Mood ratings will be used to determine response to estradiol withdrawal.


Perimenopausal Depression

MedlinePlus related topics: Depression Menopause
Drug Information available for: Depogen Estradiol Estradiol 3-benzoate Estradiol acetate Estradiol cypionate Estradiol dipropionate Estradiol valerate Polyestradiol phosphate
U.S. FDA Resources
Study Type: Observational
Official Title: The Effects of Acute Withdrawal of Estradiol on Mood Symptoms in Women With Perimenopausal Depression

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 60
Study Start Date: May 2003
Detailed Description:

Perimenopause-related mood disorders cause significant distress to a potentially large number of women. Recent studies have reported the therapeutic benefits of estradiol in women with these mood disorders; however, a relevant pathophysiologic role of declining estradiol secretion during the perimenopause has not been demonstrated. In this protocol we wish to investigate the effects of acute withdrawal of estradiol on mood under placebo controlled conditions. Thus, mood and behavior symptoms may be precipitated by the experimental conditions of this protocol. This protocol will address the following hypothesis: women with a past history of perimenopause-related depression but not women without such a history will experience a recurrence of mood and behavioral symptoms during acute estradiol withdrawal but not during continued estradiol administration. The nature of the relationship between the declining secretion of estradiol and mood in perimenopausal depressed women will be examined as follows: Peri- and postmenopausal women reporting the onset of depression during the perimenopause and who report remission of depressive symptoms on estrogen therapy (ET) will be withdrawn from ET under blinded and placebo-controlled conditions. We will recruit as a comparison group asymptomatic women on hormone replacement and without a history of perimenopause-related depression. During a three week baseline phase, all women will be switched from their current form of hormone replacement therapy to estradiol and will complete symptom ratings to confirm the absence of mood symptoms prior to entry into the study. After the screening, all women will be randomized to receive either estradiol or placebo for an additional three weeks. Comparison of mood ratings during these contrasting treatment conditions will allow us to examine the specific role of estrogen withdrawal in depression that is responsive to ET.


Ages Eligible for Study:   45 Years to 65 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Subjects for this study will meet the following criteria:

Women with a past perimenopause-related depression (within 12 years) and whose depression responded to ET will be recruited to participate in this randomized, parallel-design, double-blind, placebo-controlled study.

Women with histories of either perimenopausal depression that was not responsive to ET or hormone replacement therapy-induced dysphoria due to either the estrogen or the progesterone components of their hormone replacement will be excluded.

The diagnosis of perimenopause-related depression will be based on a history of a past depressive episode (major or minor depression confirmed by SCID or SADS-L, respectively) at midlife in association with menstrual cycle irregularity and the history of remission (also confirmed by SCID or SADS-L) of this depression after ET.

Additionally, all women will report that they were placed on HRT for the treatment of perimenopausal symptoms, including depression. To control for the effects of the hormonal manipulations in this protocol, we will also recruit a group of asymptomatic controls on ET and with no previous history of perimenopause-related depression or HRT-induced dysphoria.

Age 45 to 65;

In good medical health.


The following conditions will constitute contraindications to participate in this protocol:

  1. past history of severe major depression with suicidal ideation
  2. current treatment with antidepressant medications
  3. history of ischemic cardiac disease, pulmonary embolism, or thrombophlebitis
  4. renal disease
  5. hepatic dysfunction
  6. women with a history of carcinoma of the breast
  7. women with a history of uterine cancer, ill-defined pelvic lesions, particularly undiagnosed ovarian enlargement, undiagnosed vaginal bleeding
  8. pregnant women
  9. cerebrovascular disease (stroke)
  10. recurrent migraine headaches
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00060736

Contact: Patient Recruitment and Public Liaison Office (800) 411-1222 prpl@mail.cc.nih.gov
Contact: TTY 1-866-411-1010

United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
  More Information

NIH Clinical Center Detailed Web Page  This link exits the ClinicalTrials.gov site

Study ID Numbers: 030175, 03-M-0175
Study First Received: May 9, 2003
Last Updated: July 18, 2008
ClinicalTrials.gov Identifier: NCT00060736  
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Hormone Replacement
Gonadal Steroids
Major Depression
Minor Depression
Perimenopausal Depression

Study placed in the following topic categories:
Estradiol valerate
Depressive Disorder, Major
Estradiol 17 beta-cypionate
Depressive Disorder
Behavioral Symptoms
Mental Disorders
Estradiol 3-benzoate
Mood Disorders
Polyestradiol phosphate

ClinicalTrials.gov processed this record on January 30, 2009